Hiv Prevention
latest news & developments
SA and Zambia’s HIV shot dilemma: Demand versus supply
South Africa and Zambia are grappling with a significant challenge in rolling out lenacapavir, a new six-monthly HIV prevention injection. Despite high demand and promising early…
#Aids2026: Bhekisisa analysed SA’s first LEN roll-out data. Here's what it found
South Africa accounts for over half of all lenacapavir (LEN) users in Africa, with health department data revealing 31,297 of the continent's roughly 60,000 users are in the…
#Aids2026: Daily pill. Monthly pill. Six-monthly jab. Why choice matters
For the first time, Merck has granted generic manufacturers, including three African companies, permission to produce an investigational monthly HIV prevention pill, alimatravir,…
180 000 infections in 2024, 47 000 by 2045 — if SA rolls out the twice-a-year HIV prevention jab fast enough
The HIV prevention shot, lenacapavir, will be rolled out at South African clinics within the next couple of months and from 2027, the health department will also buy generics.…
What will HIV funding look like in 2026?
After a year of US funding cuts across global public health, including South Africa’s hard-hit HIV programmes, new realities are settling in
Here’s what’s on South Africa’s 2026 public health agenda
We talked to experts in obesity, tobacco, artificial intelligence, HIV, TB and the NHI to find out what we can expect — and what we can’t — this year
KZN rolls out controversial circumcision device amid safety concerns
The safety and track record of the CircumQ devices has been questioned
SA’s first batch of LEN jabs will arrive in February. Use Bhekisisa’s dashboard to find out who should get them
Who should get what slice of the pie once the medicine is available in public clinics? And are numbers alone what would drive decisions?
Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily prevention pill
Hetero and Dr Reddy’s will be funded by the Gates Foundation and Unitaid to produce and sell the twice-a-year anti-HIV shot around R692 per person a year
Small win for activists, but SA’s HIV projects won’t reopen
The $400 million the United States congress removed from a list of funding programmes the Trump administration wants to cut doesn’t cancel the cuts to HIV and TB programmes made…
SA gets R520 million to buy the twice-a-year anti-HIV jab – but there’s a snag
The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it has already been awarded and was cut by 16% in June
How this Limpopo NGO prepared for Trump’s funding cuts
The Anova Health Institute, which received the lion’s share of the US President’s Emergency Plan for Aids funding in South Africa, had its support halted in February along with…
The six-monthly anti-HIV jab could end Aids in SA by 2032
A modelling study released in March gives a clue at which price the jab, lenacapavir, would be worth the health department’s while
Trump ends SA’s HIV and TB research grants
Cancellation letters, which end millions of rands of South African universities’ US-government funded HIV and TB research grants with immediate effect, started to roll in over…
South Africa to roll out HIV prevention injection CAB-LA in clinics, with US donation
CAB-LA virtually eliminates someone’s chances of contracting HIV, but costs about four times more than the government can afford to pay